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Identifying therapeutic targets for cancer treatment relies
on consistent changes within particular types or sub-types
of malignancy. The ability to deﬁne either consistent
changes or sub-types of malignancy is often masked by
tumor heterogeneity. To elucidate therapeutic targets in
cutaneous squamous cell carcinoma (cSCC), the most
frequent skin neoplasm with malignant potential, we have
developed an integrated approach to gene expression
proﬁling beginning with primary keratinocytes in culture.
Candidate drivers of cSCC development were derived by
ﬁrst deﬁning a set of in vitro cancer genes and then
comparing their expression in a range of clinical data sets
containing normal skin, cSCC and the benign hyper-
proliferative condition psoriasis. A small interfering RNA
(siRNA) screen of the resulting 21 upregulated genes has
yielded targets capable of reducing xenograft tumor
volume in vivo. Small-molecule inhibitors for one target,
Polo-like kinase-1 (PLK1), are already in clinical trials
for other malignancies, and our data show efﬁcacy in
cSCC. Another target, C20orf20, is identiﬁed as being
overexpressed in cSCC, and siRNA-mediated knockdown
induces apoptosis in vitro and reduces tumor growth
in vivo. Thus, our approach has shown established and
uncharacterized drivers of tumorigenesis with potent
efﬁcacy as therapeutic targets for the treatment of cSCC.
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Introduction
Keratinocyte skin cancers are the most common
neoplasm in Caucasian populations, with an estimated
incidence of over 100000 per year in the United
Kingdom (http://info.cancerresearchuk.org/cancerstats/
types/skin/incidence/) and a cumulative risk of 70% in a
70y old Australian male (Staples et al., 2006). Cutaneous
squamous cell carcinoma (cSCC) is the most common
keratinocyte skin cancer with malignant potential and
patients presenting with regional metastasis have a poor
outcome: 5-year survival in this group is 25–50%
(Epstein, 1984; Veness et al., 2007). In the United
Kingdom, over 1 in 4 skin cancer deaths can be
attributed to non-melanoma skin cancer, principally
cSCC (ISD Scotland; http://www.isdscotland.org/isd/
183.html). High-risk groups exist where cSCC is a
major complication resulting in considerable morbidity
and mortality. Organ transplant patients are at a
greater than 100-fold increased chance of developing
cSCC, leading to a high burden of malignancy
(Euvrard et al., 2003), whereas patients with the genetic
skin-blistering disease, recessive dystrophic epidermoly-
sis bullosa (RDEB), suffer unprecedented terminal
metastasis with over 80% mortality, making cSCC the
usual cause of death for this patient group (Fine et al.,
2009).
Treatment is always required for cSCC and princi-
pally consists of excision and/or radiotherapy for local
disease control, with a paucity of options for recurrent
and metastatic disease. Pursuit of targeted therapies
capable of halting growth and spread of cSCC remains a
clear research goal. Recent success with targeted
therapies for the treatment of chronic myeloid leukemia,
HER2-ampliﬁed and BRCA-mutated tumors shows that
this goal is achievable and holds great potential (Druker
et al., 2001; Piccart-Gebhart et al., 2005; Fong et al.,
2009). Screening for cancer targets is hampered by
tumor complexity and heterogeneity coupled with
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www.nature.com/oncdifﬁculties in distinguishing between drivers of tumor
characteristics and the characteristics themselves (Merlo
et al., 2006). Furthermore, pathways important for
cancer are frequently inherent to normal cell function,
resulting in clinically limiting side effects when success-
fully targeted (Cheng and Force, 2010).
In this study, we use the ability to culture primary
keratinocytes and use an integrated gene expression
proﬁling approach to derive a small set of tumor-speciﬁc
genes, which we screen with a small interfering
RNA (siRNA), and identify both existing and novel
cancer targets capable of speciﬁcally inducing tumor cell
apoptosis.
Results
Primary cSCC keratinocytes readily form tumors in vivo
irrespective of histological grade
In order to model human cSCC without the need for
genetic manipulation, we isolated keratinocytes directly
from fresh tumor material as described (Rheinwald and
Beckett, 1981). To study life-threatening cSCC, we
processed tumors that presented with metastasis derived
from immunocompetent and immunosuppressed pa-
tients, as well as tumors derived from patients with
RDEB. We also used cSCC keratinocytes isolated from
well-differentiated tumors that did not present with
metastasis and non-cSCC primary epidermal keratino-
cytes (from either routine reduction surgery or normal
skin obtained at the time of cSCC surgery). Supplemen-
tary Table S1 details the patient donors who provided
the tumor samples used in this study. All tumor
keratinocytes showed clear genetic alterations as deter-
mined by single-nucleotide polymorphism mapping
array hybridization and cytogenetic analysis, whereas
all peritumoral normal keratinocytes did not (Supple-
mentary Tables S2–S3; Supplementary Figure S1, and
data not shown).
Five of eight cSCC keratinocyte populations readily
formed tumors in severe combined immunodeﬁcient
(SCID) mice; 1/8 of the populations consistently formed
squamous cysts, which failed to reach a volume of
100mm
3 and 2/8 the tumor populations tested did not
grow after 120 days (Figure 1a). Xenograft tumors were
readily recognized as human cSCC with varied histolo-
gical grade (Figure 1b). In vivo growth was not restricted
to moderately or poorly differentiated tumors, or those
derived from patients with RDEB (Figure 1 and
Supplementary Table S1).
Primary cSCC keratinocytes are heterogeneous with
respect to genetic alteration and cSCC marker expression
In agreement with previous studies, no consistent
genetic alterations were observed across all cSCC
populations (Supplementary Table S2) (Purdie et al.,
2009). Chromosome 8q gain was observed in 7/8 cSCC
keratinocyte populations and this correlated with an
increase in C-myc expression, an oncogene associated
with squamous cell carcinoma (SCC) development
(Supplementary Figure S2A) (Pelengaris et al., 1999).
To further characterize our cSCC keratinocyte popula-
tions, we investigated additional genes, proteins and
pathways reported to be important in both human and
mouse cSCC, and looked for patterns, which might
separate xenograft tumor-forming capability or patient
group. p53 and p16 expression varied among cSCC
keratinocytes (Supplementary Figure S2B) and we
detected TP53 mutations in all eight populations
examined (Supplementary Table S1). Phospho-STAT3
expression varied but was consistently increased across
all cSCC as compared with primary non-SCC keratino-
cytes, in agreement with previous reports (Suiqing et al.,
2005) (Supplementary Figure S2C). No consistent
evidence of activated RAS (determined by antibody
detection of GTP-bound RAS) was observed in
tumorigenic cultured cSCC keratinocytes as compared
with normal primary or non-tumorigenic cSCC human
keratinocytes (Supplementary Figures S2D and E).
Comparison of gene expression clearly separates normal
keratinocytes from cSCC keratinocytes in quiescent
culture
We then performed gene expression analysis using
cultures of early-passage primary cells. We chose to
use conﬂuent cultures to best mimic the close cell–cell
proximity of keratinocytes in vivo and to eliminate
changes in gene expression caused by divergent pro-
liferation rates—under the culture conditions used here
for RNA harvest, all cells, tumor and normal, showed
similar quiescent growth rates (Figure 2a). Un-super-
vised clustering of normalized array signal intensities
clearly segregated normal skin from cSCC (Figure 2b).
A comparison between the different sample groups
based on normal skin, RDEB skin, cSCC and RDEB
cSCC keratinocytes, as well as xenograft tumor histol-
ogy, or tumor-forming ability, showed that the highest
number of differentially expressed genes were identiﬁed
comparing all cSCC with all non-cSCC cultures
(Supplementary Table S4). This analysis deﬁned 435
in vitro differentially expressed cSCC genes (Supplemen-
tary Table S5).
Thirty-ﬁve percent of in vitro cSCC genes are expressed
concordantly across three independent in vivo data sets
To identify clinically relevant genes from our in vitro
cSCC gene set, we analyzed the expression of all probes
representing each of the 435 genes in three separate
tissue expression data sets containing primary cSCC and
normal skin samples. We performed our own experi-
ment comparing RNA isolated from fresh frozen cSCC
(n¼9) and non-cSCC skin (n¼5), and interrogated data
from two publicly available experiments (GDS2200
(Nindl et al., 2006) and GSE7553 (Riker et al., 2008)).
In agreement with recent observations that little overlap
exists between the gene expression proﬁling of cutaneous
or head-and-neck SCC when stringent ﬁltering criteria
are applied (Van Haren et al., 2009; Braakhuis et al.,
2010), probes representing only six of our 435 gene
signature were returned as signiﬁcantly differentially
expressed across all three in vivo data sets based on
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Oncogeneaverage fold change >2 and Po0.005 (Supplementary
Table S6). However, when using an average fold change
of 20%, probes representing 154 of the 435 genes were
concordantly expressed across all three separate array
platforms, suggesting that a large proportion of the
genes identiﬁed in culture are relevant to cSCC
pathology. This analysis deﬁned a set of 154 in vivo
cSCC genes (Supplementary Table S7).
Comparison with the benign hyper-proliferation disorder
psoriasis identiﬁes 37 genes as potential drivers of cSCC
Differentially expressed tumor genes can be either a
driver or a consequence of disease state. One approach
to identify tumor-speciﬁc changes is to compare gene
expression with comparable benign conditions. Psoriasis
offers such a point of comparison as this disease,
although completely benign, harbors massive hyper-
proliferation, as well as a reactive inﬂammatory
response (Haider et al., 2006). A comparison between
fold change of psoriasis lesional versus psoriasis
non-lesional skin (average of data sets GSE13355 and
GSE14905 (Romanowska et al., 2010)), and fold change
of cSCC versus normal skin (average of data sets in
Supplementary Table S7), showed a striking relationship
between expression (r
2¼0.84) indicating that the ma-
jority of our 154 in vivo cSCC genes were dysregulated
similarly in psoriasis (Figure 2c and Supplementary
Table S8). Thirty-seven genes did not show similar fold
change in psoriasis (Figure 2c and Supplementary Table
S9) and we therefore designated these genes as ‘cSCC-
speciﬁc’.
Twenty-two percent of in vivo cSCC genes are
differentially regulated in vitro
Of the 37 cSCC-speciﬁc genes only 29 were similarly
differentially regulated in vitro compared with in vivo;
eight genes were differentially expressed (cSCC versus
normal) in an opposite manner (Supplementary Table
S9). This percentage was identical across all 154 in vivo
cSCC genes: 34 (22%) were discordantly regulated
Figure 1 cSCC keratinocytes readily form tumors in SCID mice with identical histology to human cSCC. Female SCID Balb/c mice
were subcutaneously injected in the right ﬂank with 1–4 10
6 tumor cells mixed with high-concentration Matrigel (Becton Dickinson).
Tumor volumes were measured twice a week with calipers and calculated using the formula, V¼p4/3((LþW)/4)3, were L is the length
and W is the width. (a) Representative growth of a single tumor from eight separate cSCC keratinocyte populations. The average
number of days to reach a volume of 100mm
3 from 1–4 separate experiments was as follows: SCCRDEB2 (49 days±5.6 s.d., n¼3),
SCCIC1 (11.8 days±3.4 s.d., n¼12), SCCT2 (59.7 days±8.1 s.d., n¼3), SCCT3 (128.3 days±11.7 s.d., n¼3) and SCCT8 (65
days±7.1 s.d., n¼2). (b) H&E-stained sections of a representative xenograft tumor for each of the six cell populations that showed
measurable growth in mice ( 100 magniﬁcation). cSCC, cutaneous squamous cell carcinoma; H&E, hematoxylin and eosin; SCID,
severe combined immunodeﬁcient.
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Oncogenein vitro compared with in vivo (Supplementary Tables S5
and S7). Gene ontology analysis showed that these
discordantly expressed genes were disproportionately
involved in the cytoskeleton or signal transduction
(Supplementary Figure S4), suggesting that cellular
context is important for their expression. Because of
the discordant nature of their expression, we chose not
to pursue these eight cSCC-speciﬁc genes and focused
on the remaining 29 cSCC-speciﬁc genes, which were
similarly regulated (relative to normal skin) in vitro and
in vivo. Supplementary Figure S3 provides a ﬂow
diagram detailing how we derived this gene set.
RNA interference screen identiﬁes PLK1 and C20orf20
as genes critical for tumor cell survival
As 21 of the remaining 29 cSCC-speciﬁc genes were
upregulated, we screened two cSCC keratinocyte popu-
lations, SCCIC1 and SCCRDEB2, by siRNA knock-
down of each gene individually and assessing cell
viability by a colorimetric assay of mitochondrial
dehydrogenase activity. All three duplexes targeting
Polo-like kinase-1 (PLK1) and C20orf20, either indivi-
dually or pooled, consistently reduced cell viability in a
high-throughput format (Supplementary Figure S5).
Three further potential targets showed ‘hits’ consistently
with 2/3 siRNAs (Supplementary Figure S5).
PLK1 knockdown and inhibition induces signiﬁcant G2/M
arrest and apoptosis in cSCC keratinocytes compared
with normal-proliferating keratinocytes
Both RNA interference-mediated depletion of PLK1
and activity inhibition using the small-molecule inhibi-
tors BI 2536 and GW843682X resulted in a potent
reduction of cell viability in cSCC cells, with little
effect on the growth of normal primary keratinocytes
at comparable doses (Figures 3a and b). siRNA
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Figure 2 Expression proﬁling of quiescent cultures of early-passage keratinocytes separates cSCC from normal and identiﬁes
potential tumor drivers in vivo.( a) Growth rates of keratinocytes used in this study as assessed by a colorimetric assay of mitochondrial
dehydrogenase activity when seeded at low density (upper panel) or at conﬂuence (lower panel). Conﬂuent keratinocytes are quiescent
after 48h of culture. RNA for subsequent array experiment was isolated between 48 and 56h after conﬂuence. (b) An un-supervised
clustering dendrogram of in vitro gene expression data generated by BRB-ArrayTools v3.8.1. cSCC keratinocyte samples (red box)
cluster independently of non-cSCC keratinocyte samples (blue box). (c) Average cSCC versus normal skin (NS) fold change for all 154
concordantly expressed in vivo cSCC genes plotted against average psoriatic lesional skin versus psoriatic non-lesional skin (NLS) fold
change shows a strong overall correlation (r
2¼0.84) and identiﬁes genes speciﬁcally differentially regulated in cSCC. cSCC, cutaneous
squamous cell carcinoma; EBKs, primary non-SCC RDEB keratinocytes; NHKs, primary normal human keratinocytes. A full colour
version of this ﬁgure is available at the Oncogene journal online
C20orf20- and PLK1-targeted therapy for cSCC
SA Watt et al
4669
Oncogeneknockdown of PLK1 was performed more than 10 times
in cSCC cells (SCCRDEB2 and SCCIC1) and ﬁve times
in normal primary keratinocytes. On each separate
occasion, a signiﬁcant reduction in viability when
compared with scrambled non-targeting control was
seen in cSCC cells, whereas no signiﬁcant change was
observed in normal primary keratinocytes using the
MTS assay as described (Po0.05; Figure 3a and data
Figure 3 PLK1 knockdown and inhibition induces signiﬁcant G2/M arrest and apoptosis in cSCC keratinocytes compared with that
in normal-proliferating keratinocytes. (a) SCCRDEB2 (SCCK) keratinocytes and primary normal human keratinocytes (NHKs) were
transfected with a pool of three separate siRNAs targeting PLK1 and both cell viability and PLK1 protein expression were determined.
The percentage of viable cells relative to time 0 (T0) is shown. Whole-cell lysate was extracted from the same SCCRDEB2
keratinocytes or NHKs treated with the same transfection reagent mix at the same time as those used for the viability assessment
shown, and PLK1 protein levels were determined by western blotting (lower panel). All results shown represent the mean±s.d.;
***Po0.001 compared with the scrambled control siRNA (SCR) (n¼3). (b) The SCCIC1 (SCCK) keratinocytes and NHKs cell
viability time course over 72h of treatment with the PLK1 inhibitors BI 2536 (top panel) and GW843682X (bottom panel). The
percentage viable cell number is shown relative to values at T0 (o100% represents a net decline in cell number, >100% represents a
net increase in cell number). Representatives of a minimum of three experiments are shown. The results shown represent the
mean±s.d., n¼3. The NHKs used in each experiment were isolated from different donors. (c) Whole-cell lysate was extracted from
SCCIC1 keratinocytes and subjected to western blot analysis of PLK1 protein levels 24h after exposure to 10mM GW843682X or 5mM
BI 2536 as indicated. (d) Cell-cycle analysis in SCCIC1 keratinocytes treated either with a pool of three separate PLK1 targeting
siRNA (top panel) or with the PLK1 inhibitors GW843682X (10mM) and BI 2536 (5mM) (bottom panel), and stained for BrdU and
propidium iodide. Results expressed as percentage of cells at the G0/G1, S and G2/M phases of cell cycle 20 or 16h following treatment,
respectively. The results shown are the mean±s.d. of three independent experiments. (e) SCCIC1 keratinocytes transfected with a pool
of three separate siRNAs targeting PLK1 or a cell death-positive control siRNA (upper panel), or treated with GW843682X (10mM)
and BI 2536 (5mM) (lower panel), were assayed for induction of apoptosis using a Cell Death Detection ELISA 24 or 20h after
treatment. The results show the fold increase in absorbance associated with increased cytoplasmic nucleosomes relative to scrambled
control non-targeting siRNA or drug vehicle control, respectively. Shown is a representative experiment, with each experiment
performed a minimum of three times. The results are the mean±s.d., n¼3; *Po0.05, **Po0.01, ***Po0.001 compared with
the control. BrdU, 5-Bromodeoxyuridine; cSCC, cutaneous squamous cell carcinoma; PLK, Polo-like kinase; siRNA, small
interfering RNA.
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Oncogenenot shown). Knockdown of PLK1 at the level of protein
expression relative to actin was assessed by western
blotting on three separate occasions and the extent of
knockdown ranged from 48.4 to 80.8% in cSCC and 43
to 80.2% in normal primary keratinocytes (Figure 3a,
and data not shown). GW843682X did not affect
normal primary keratinocyte growth, whereas only very
high doses of the inhibitor BI 2536 reduced the viability
of proliferating normal primary keratinocytes
(Figure 3b). In agreement with separate studies evaluat-
ing BI 2536 in chronic myeloid leukemia (Gleixner et al.,
2010) and GW843682X in melanoma (Schmit et al.,
2009b), western analysis showed that, unlike exposure to
GW843682X, BI 2536 signiﬁcantly reduced the amount
of PLK1 protein after 24h (Figure 3c). Cell-cycle
analysis showed an accumulation of cells at the G2/M
phase following PLK1 inhibition and depletion
(Figure 3d), and a cell death detection ELISA showed
substantial induction of apoptosis, through an increase
in cleaved nucleosomes in the cytoplasm, following both
PLK1 inhibition and depletion in cSCC cells (Figure 3e).
The concentration of the inhibitor BI 2536 needed for
half-maximal growth inhibition (EC50) of SCCRDEB2,
SCCIC1 and normal primary keratinocytes in the
presence of media supplements required for normal
primary keratinocyte growth was found to be 190nM,
440nM and 2.98mM respectively.
C20orf20 knockdown induces apoptosis in cSCC cells in
the absence of cell-cycle arrest and has no measurable
effect on normal keratinocyte growth
The chromosomal segment harboring C20orf20 has
been identiﬁed as being frequently ampliﬁed in color-
ectal cancer (Carvalho et al., 2009) and cervical cancer
(Scotto et al., 2008), and most recently, in parallel to our
work, C20orf20 was identiﬁed as being overexpressed in
colorectal cancer (Yamaguchi et al., 2010). This color-
ectal cancer study showed that a reduction of C20orf20
expression through stable short-hairpin RNA inhibited
proliferation in the colon carcinoma lines HCT116 and
SW480 (shown by a 10% decrease in S-phase replicating
cells), without evidence of apoptosis (Yamaguchi et al.,
2010). We investigated whether C20orf20 knockdown
yielded similar results in cSCC and whether any effect
on normal keratinocytes was observed. Knockdown in
cSCC resulted in reduced cell viability, with no
measurable effect on normal keratinocytes under similar
conditions (Figure 4a). siRNA knockdown of C20orf20
was performed more than 20 times in cSCC cells
(SCCRDEB2 and SCCIC1) and eight times in normal
primary keratinocytes. On each separate occasion, a
signiﬁcant reduction in viability when compared with
scrambled non-targeting control was seen in cSCC cells,
whereas no signiﬁcant change was observed in normal
primary keratinocytes using the MTS assay as described
(Po0.05; Figure 4a, and data not shown). Knockdown
of C20orf20 relative to actin was assessed by reverse
transcription–real-time quantitative PCR on two sepa-
rate occasions and the extent of knockdown was found
to be 64.3 and 89.4% in cSCC, and 51.9 and 72.3% in
normal primary keratinocytes (Figure 4a, and data
not shown). Depletion in cSCC induced a signiﬁcant
apoptotic response in the absence of any change
in cell-cycle parameters (Figure 4b and c), the opposite
to that seen in colorectal cancer cell lines. In agreement
with the previous study, knockdown of C20orf20 in the
HCT116 cells did not show an increase in apoptosis
(Yamaguchi et al., 2010) (Figure 4b), indicating either a
more potent effect in cSCC or a different mode of
action.
PLK1 inhibition and C20orf20 siRNA knockdown target
cSCC in vivo
To assess the in vivo action of PLK1 inhibition and
C20orf20 depletion we injected either the PLK1
inhibitor BI 2536 or a C20orf20-targeting siRNA into
established SCCIC1 xenograft tumors. In each case we
saw direct evidence of effective tumor targeting
(Figure 5a). In as little as 2 weeks, tumors harvested
from animals treated with BI 2536 showed marked
reduction in the presence of tumor keratinocytes
compared with vehicle controls (Figure 5b). Treatment
with C20orf20 siRNA reduced tumor volume over time
compared with a non-targeting siRNA control
(Figure 5a). The largest C20orf20 siRNA-treated tumors
showed marked reduction in the number of tumor
keratinocytes present and were hollow in appearance
(Figure 5c).
Discussion
Our approach to target identiﬁcation has yielded deﬁnite
therapeutic targets for cSCC in the form of PLK1 and
C20orf20 (Figure 5). The discovery that PLK1 is
overexpressed and required for survival in cSCC cells
mirrors observations in a number of different tumor
types (Takai et al., 2005). In agreement with our
ﬁndings, a recent study has shown PLK1 overexpression
in cSCC using immunohistochemical staining of tissue
arrays (Schmit et al., 2009a). Here, we show that cSCC
keratinocytes undergo established hallmarks of PLK1
inhibition and depletion; mitotic arrest, inhibition of
proliferation and apoptosis, and as reported previously,
cell death occurs, preferentially in cancer cells compared
with normal cells, thus providing a therapeutic window
(Liu et al., 2006; Schmit and Ahmad, 2007; Schmit et al.,
2009b) (Figure 3). Normal cells require knockdown of
p53 in addition to PLK1 to invoke cell death (Liu et al.,
2006), and various reports suggest increased sensitivity
to PLK1 inhibition when p53 is defective (Guan et al.,
2005; Degenhardt and Lampkin, 2010). This is espe-
cially pertinent in the case of cSCC as both our data and
that of others show the majority of cSCC to harbor
TP53 mutation (Supplementary Table S1) (Giglia-Mari
and Sarasin, 2003). The potential of PLK1 as a
therapeutic target that could be fast-tracked into human
trials for cSCC is enhanced by the fact that a number of
small-molecule inhibitors are already in clinical devel-
opment (Schoffski, 2009; Degenhardt and Lampkin,
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Oncogene2010). Among these, the inhibitor BI 2536 has pro-
gressed to phase-II trials for both hematological and
solid-tumor malignancies (http://www.clinicaltrials.
gov), and is shown here to have dramatic efﬁcacy in
treating cSCC in vivo (Figure 5). We show that in vitro
cSCC keratinocytes are up to 16 times more sensitive to
the inhibitor BI 2536 than normal primary keratino-
cytes. Together, these data suggest that targeting PLK1
has great promise for effective cSCC therapy.
Our observation that knockdown of C20orf20 can
induce apoptosis and reduce tumor growth in cSCC
highlights this gene, and the histone acetyltransferase
complex (TIP60 HAT) with which it associates, as
potential targets for therapeutic development. C20orf20
depletion in cSCC resulted in reduced cell viability
attributable to induction of apoptosis at levels compar-
able with PLK1 knockdown, and without effect on cell
cycle (Figure 4). This is in contrast to recent data on
colorectal cancer cells, which we conﬁrm here showing a
reduction in proliferation without engagement of
apoptosis (Yamaguchi et al., 2010). In addition,
normal keratinocytes, which express this gene at very
low levels, remain unaffected by C20orf20 knockdown
(Figure 4a).
C20orf20 was initially identiﬁed as a protein capable
of binding to two components of the TIP60 HAT
complex, MRG15 and MRGX (Bertram and Pereira-
Smith, 2001; Cai et al., 2003). MRG15 and MRGX are
stable components of both HAT and histone deacetylase
complexes, and overexpression of C20orf20, which
speciﬁcally associates with TIP60 HAT, has been shown
to increase their protein levels, indicating regulation of
stability and/or synthesis (Hayakawa et al., 2007). It has
been suggested that C20orf20 inﬂuences the acetylation
of histones and potentially transcription factors such as
p53 (Gu and Roeder, 1997), by controlling the balance
of MRG proteins associated with either TIP60 HAT or
histone deacetylase complexes (Hayakawa et al., 2007).
In the study by Yamaguchi et al. (2010), knockdown of
another TIP60 HAT C20orf20-binding partner, BRD8,
produced effects similar to C20orf20 depletion. It is
possible that the effects of C20orf20 are mediated
through interaction with other HAT complex proteins,
and it will be necessary to systematically knockdown
these components to identify functional partners speciﬁc
to cSCC. Because of the increased potency seen in cSCC
compared with that in colon cancer it is tempting to
speculate that C20orf20 is ‘wired’ differently in different
Figure 4 C20orf20 knockdown induces apoptosis in cSCC cells without cell-cycle arrest, with no measurable effect on normal
keratinocyte growth. (a) SCCIC1 keratinocytes and primary normal human keratinocytes (NHKs) were transfected with a pool of
three separate siRNAs targeting C20orf20 (C20) or a scrambled non-targeting control siRNA (Scr), and cell viability was assessed by
MTS assay (left panel). The results shown are 48h after seeding of transfected cells and expressed relative to T0. The relative expression
of C20orf20 following siRNA transfection was assessed by reverse transcription–real-time quantitative PCR on the same cells treated
with the same transfection reagent mix at the same time as those used for the viability assessment shown, with all data shown relative to
the NHK scrambled non-targeting control (right panel). (b) SCCIC1 keratinocytes and HCT116 colorectal cancer cells were
transfected with a scrambled non-targeting control, a cell death-positive control or a pool of three separate C20orf20 targeting siRNA,
and apoptosis was assessed 24h later by a Cell Death Detection ELISA. The results show the fold increase in absorbance associated
with increased cytoplasmic nucleosomes relative to non-targeting siRNA. Shown is a representative experiment, with each experiment
performed a minimum of three times. The results are the mean±s.d., n¼3; **Po0.01, ***Po0.001 compared with the control. (c)
Cell-cycle analysis in SCCIC1 keratinocytes treated with C20orf20 siRNA. Cells were incubated for 20h after transfection and labeled
with BrdU and propidium iodide. Results expressed as percentage of cells at the G0/G1, S and G2/M phases. The results shown are the
mean ±s.d. of three independent experiments. BrdU, 5-Bromodeoxyuridine; cSCC, cutaneous squamous cell carcinoma; siRNA, small
interfering RNA.
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Oncogenetumor types, leading to varied responses upon reduced
expression. It should be noted that expression at the
mRNA level was around two-fold higher in cSCC cells
compared with that in HCT116 cells (data not shown),
perhaps indicating a greater C20orf20-dependent pro-
survival drive in cSCC than in colon carcinoma. It will
be important to investigate the mode of action for
C20orf20-speciﬁc apoptotic induction to clarify its
potential as a cancer target.
By identifying both PLK1 and C20orf20 as demon-
strable cancer targets we re-enforce the notion that
although cultured tumor cells fall short of faithfully
replicating the complex nature of human cancers, they
are nevertheless invaluable in our goal to understand
and ultimately treat this disease (Masters, 2000; Sharma
et al., 2010). The majority of arguments against the use
of cultured cells to investigate tumor biology are based
on the marked differences seen in the expression
proﬁling of cultured cancer cells compared directly with
tumor tissue (Perou et al., 1999; Ross et al., 2000; Welsh
et al., 2001; Dairkee et al., 2004). Few examples exist
where normal cells are included in such analysis and in
these cases, expression proﬁles in culture, as would be
expected from disparate environments, cluster sepa-
rately from tissue (Perou et al., 1999). The use of
quiescent, conﬂuent cultures represents a departure
from traditional in vitro mRNA expression experiments,
which use cultures growing in the log phase, typically
considered ‘healthy’ (Perou et al., 1999; Welsh et al.,
2001). This was prompted by observations that junction
complexes can take 48h to mature in cultured kerati-
nocytes (Wallis et al., 2000; South et al., 2003) and that
varying cell–cell adhesion can modulate numerous
signaling cascades (Wu and Bonavida, 2009). By using
cultured material we have been able to assess gene
expression in the absence of a surrounding microenvir-
onment and supported by the cells own matrix.
Although it is well documented that this does not reﬂect
the situation in vivo (Weaver et al., 1997; Creighton
et al., 2003), it has enabled us to compare tumor with
normal in the absence of variation resulting from tumor
heterogeneity. In doing so we make the following
observations: RDEB cSCC keratinocytes possess ex-
pression proﬁles similar to other cSCC, indicating
Figure 5 PLK1 inhibition and C20orf20 knockdown reduces tumor growth in vivo.( a) Top panel: SCCIC1 tumors treated with the
PLK1 inhibitor BI 2536. Treatment group tumors (n¼3) were injected with BI 2536 at a dose of 25mg/kg, six times over 2 weeks
(arrows). The control group (n¼2) was injected with the vehicle following the same schedule. Bottom panel: SCCIC1 tumors treated
with C20orf20 siRNA. Treatment group (n¼3) tumors were injected with 580pmol of a pool of three separate C20orf20 targeting
siRNA duplexes in 100ml of phosphate-buffered saline. The control group (n¼3) was injected with 580pmol of a scrambled non-
targeting control siRNA duplex in 100ml of phosphate-buffered saline. The animals were killed 2 days after the last treatment. (b)A
representative H&E-stained section (top) and a keratin-immunostained section (bottom) of control (left) and BI 2536-treated (right)
SCCIC1 tumors after 2 weeks of treatment. Although no difference in tumor volume between the control and the treated group was
seen at this time point, histology shows that the BI 2536-treated tumors consisted of mainly inert material (keratin) without discernable
SCCIC1 tumor cells, whereas control tumors contained numerous SCCIC1 cells ( 100 magniﬁcation). (c) Photographs from the
experiment shown in panel a of vehicle- (top left, tumor bisected showing both halves delineated by the dashed line) and BI 2536-
treated (top right) SCCIC1 tumors. The largest SCCIC1 tumor treated with C20orf20 siRNA in the experiment shown in panel a
(bottom right, tumor bisected, showing both halves delineated by a dashed line) is hollow in appearance compared with the scrambled
non-targeting control siRNA-treated tumor (bottom left). H&E, hematoxylin and eosin; PLK, Polo-like kinase; siRNA, small
interfering RNA.
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even after using a quiescent in vitro model, many of the
‘cSCC-speciﬁc’ genes identiﬁed are involved in the cell
cycle and proliferation (BUB1, PLK1, CDC25C,
WDHD1; Supplementary Table S9), in keeping with
features common to all cancers (Hanahan and Wein-
berg, 2000) and suggesting that dysregulation of the cell
cycle is apparent even in the absence of marked
proliferation differences. We believe that the strategy
described here will be applicable to epithelial cancers
where culture of primary cells is well established
(Brattain et al., 1981; Rheinwald and Beckett, 1981;
Smith et al., 1981; Burns et al., 1993).
In summary, we have used an integrative approach
including expression proﬁling and in vivo assays to
identify novel targets in cSCC. We hope this work will
lead to the use of PLK1 inhibitors in the treatment of
cSCC and to the development of targeted therapies
based around the biology of C20orf20.
Materials and methods
All human samples were collected after informed, written
consent and in accordance with the Helsinki guidelines. All
animals were used in accordance with the UK Home Ofﬁce
regulations.
Keratinocyte isolation and growth
Primary keratinocytes were isolated from fresh tumor or
normal specimens and initially grown in the presence of a
mitotically inactivated 3T3 feeder layer as described (Rhein-
wald and Beckett, 1981). Tumor populations were veriﬁed by
single-nucleotide polymorphism mapping (Purdie et al., 2007)
or cytogenetic analysis (Cunningham et al., 2002) as described.
Normal keratinocytes were routinely expanded and passaged
no more than twice prior to experimental assays in the
presence of 3T3 cells. Tumor keratinocytes were initially
established with a 3T3 feeder layer and subsequently cultured
without. With the exception of cultures used for expression
analysis (below), all keratinocytes used in the assays described
here were cultured in the absence of 3T3 cells. All keratino-
cytes were cultured in ‘keratinocyte media’ containing 10%
serum and growth factors as described (Rheinwald and
Beckett, 1981). For expression analysis keratinocytes
were seeded in the presence of a 3T3 feeder layer and
grown to conﬂuence. One day prior to conﬂuence any
remaining adherent 3T3 cells were removed using versene
(Invitrogen, Paisley, UK) or a weak solution of trypsin/versene
(Invitrogen).
In vivo tumor growth and treatment
For tumorigenicity assays a suspension of 1–4 10
6 tumor
cells was mixed with high-concentration Matrigel (Becton
Dickinson, Oxford, UK) and injected subcutaneously into the
ﬂanks of SCID Balb/c mice. For tumor treatment 4 10
6
SCCIC1 cells were used. Tumors were measured by a caliper
and treatment began when volume reached 100mm
3.
Proliferation and cell viability assays
Colorimetric assays of mitochondrial dehydrogenase activity
were used to measure growth curves and cell viability. The
initial proliferation rates of primary cultures were determined
using Cell Proliferation Kit-I (MTT) (Roche, Burgess Hill,
UK) according to the manufacturer’s instructions. All
subsequent proliferation/viability assays were performed using
the MTS CellTitre 96 AQueous One Solution Cell Prolifera-
tion Assay (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. In each case all cells were seeded
into replica 96-well plates and readings were taken at intervals
up to a maximum of 96h. An increase in mitochondrial
dehydrogenase activity using this assay directly correlated with
cell number determined using a CASY Model TT cell counter
(Roche Diagnostics Ltd, West Sussex, UK) (data not shown).
Gene expression and analysis
According to the manufacturer’s instructions, total RNA was
extracted from cells (passage o7) or frozen tissue sections
using the RNeasy kit (Qiagen, Crawley, UK) and hybridized
to Human Hybridize 6-Sample BeadChips (whole-genome
gene expression for BeadStation) (Illumina, San Diego, CA,
USA). RNA was isolated from keratinocyte cultures 2 days
after conﬂuence. V1 arrays were used for the cell culture
analysis and V2 arrays were used for the tissue analysis. Cubic-
spline-normalized signal intensities for each probe were
determined using Illumina’s BeadStudio Data Analysis Soft-
ware. Data were analyzed by Student’s t-test. In our initial
in vitro experiment, probes were scored that met the following
three criteria: (a) Po0.001, average fold change (FC) >2.5,
with expression above the signal intensity detection threshold
of 10; (b) Po0.001, FC>1.5, with intermediate expression
(signal intensity >50); (C) Po0.005, FC>2.5, with high
expression (signal intensity >100).
For all other array analysis, average FC and Student’s t-test
P-values were generated for all probes representing each of the
435 in vitro cSCC genes where present on each of the arrays
described using normalized signal intensities either generated
in BeadStudio (our own experiment) or available at the NCBI
GEO database (http://www.ncbi.nlm.nih.gov/geo/ (Edgar
et al., 2002)).
RNA interference screen
We used the top three siRNA oligonucleotides per gene as
ranked by Sigma-Aldrich (Dorset, UK). In each experiment a
negative control (MISSION siRNA Universal Negative
Control #1; Sigma-Aldrich) and a positive control (AllStars
Hs Cell Death Control siRNA; Qiagen) were used. Cells were
seeded in 96-well plates at 5000cells/well in 100mlo f
keratinocyte media and transfected 24h later with siRNA
(40nM ﬁnal concentration) using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA, USA) diluted in Opti-MEM (Invitrogen)
according to the manufacturer’s instructions. Cell viability was
assessed at 48, 72 and 96h after transfection, and a reading
was taken at time 0 (before transfection), using the MTS
CellTitre 96 AQueous One Solution Cell Proliferation Assay
(Promega) according to the manufacturer’s instructions.
PLK1 and C20orf20 siRNA and PLK1 inhibition
For RNA interference transfection, cells were seeded in six-
well plates at 2.5 10
5cells/well and 24h later transfected as
described above. For each experiment a pool of three
individual siRNA oligonucleotides was used. Cells were left
for 16h then trypsinized, counted on a CASYModel TT
counter (Roche Diagnostics Ltd) and seeded in 96-well plates
at 3000cells/well in 100ml of keratinocyte media. Cell viability
was determined using the MTS assay as described. For small-
molecule inhibitor treatment, 50ml of cells were seeded in 96-
well plates at 3000cells/well, incubated at 371C for 2h and
then 50ml of media containing two-times-concentrated drug
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concentrations at which cellular growth was inhibited by 50%
(EC50) after 48h of treatment were extrapolated by the ﬁve-
parameter logistic model using the curve ﬁtting program
Masterplex ReaderFit 2010 (MiraiBio Group, Hitachi
Solutions America, Ltd, San Francisco, CA, USA).
Apoptosis detection
Apoptosis was detected using the Cell Death Detection
ELISA
PLUS (Roche Diagnostics Ltd). Cells were seeded in
24-well plates at 0.5 10
5cells/well for 24h and either
transfected with siRNA (three individual oligonucleotides
pooled) or treated with small-molecule inhibitors for
24 or 16h, respectively, as described, before collecting lysates
and performing ELISA according to the manufacturer’s
instructions.
Antibodies and chemicals
The antibodies and chemicals used in this study were the
following: b-Actin (mAbcam 8226; Abcam, Cambridge, UK);
PLK1 (#208G4; Cell Signaling Technology Inc, Danvers, MA,
USA); BI 2536 (Selleck Chemicals LLC, Houston, TX, USA),
GW843682X (Sigma-Aldrich); anti-BrdU antibody (Becton
Dickinson).
Protein quantiﬁcation
The amount of PLK1 protein was quantiﬁed from western blot
experiments using Image J (http://rsb.info.nih.gov/ij/) by
calculating an integrated density value through multiplication
of band area and gray intensity. This value was divided by the
corresponding value for the actin loading control to produce a
relative intensity.
Cell-cycle analysis
5-Bromodeoxyuridine (BrdU; Sigma-Aldrich) was added at
30mM ﬁnal concentration for 20min. Cells were collected and
ﬁxed by dropping a 1-ml cell suspension in phosphate-buffered
saline into 3ml ice-cold ethanol while vortexing. Pepsin
(Sigma) was added at 1mg/ml in 30mM HCL for 30min and
DNA was denatured with 2N HCL for 20min. An anti-BrdU
antibody diluted in phosphate-buffered saline/0.5% Tween/
0.5% bovine serum albumin was added for 1h followed by
30-min incubation with a ﬂuorescein isothiocyanate-sheep
anti-mouse IgG (Sigma). Propidium iodide (Sigma) was added
in the ﬁnal wash step at a concentration of 25mg/ml and
samples were analyzed using a FACScan ﬂow cytometer and
the CellQuest software (Becton Dickinson).
Real-time quantitative PCR
A5 - mg weight of RNA was incubated with random primers
and M-MLV reverse transcriptase (Promega) to generate
cDNA. For quantitative measurement of C20orf20 mRNA,
the SYBR Green Master Mix (Qiagen) was used with the
following primers: 50-ATTCTTCCATTCCCGAATCC-30 and
50-CCCAAACTCCCTGAAGATGA-30. Actin primers (50-CC
TTGCACATGCCGGAG-30 and 50-GCACAGAGCCTCGC
CTT-30) were used as internal control. The QIAgility (Qiagen)
automated PCR workstation was used to set up PCR samples;
reactions were performed using the Rotor-Gene Q (Qiagen)
and expression was calculated by the DDCT method (Livak and
Schmittgen, 2001).
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